Evidence-Based Reviews

Psychiatric considerations in menopause

Current Psychiatry. 2018 October;17(10):11-16,53

Susan Hatters Friedman, MD

Chandni Prakash, MBBS, MD

Charmian Møller-Olsen, MBBCh

Women’s risk of psychiatric symptoms and disorders is increased during menopause.

PDF Download

References

1. Bromberger JT, Kravitz HM. Mood and menopause: findings from the study of women’s health across the nation (SWAN) over 10 years. Obstet Gynecol Clin North Am. 2011;38(3):609-625.
2. Almeida OP, Marsh K, Flicker L, et al. Depressive symptoms in midlife: the role of reproductive stage. Menopause. 2016;23(6):669-765.
3. Sajatovic M, Friedman SH, Schuermeyer IN, et al. Menopause knowledge and subjective experience among peri- and postmenopausal women with bipolar disorder, schizophrenia and major depression. J Nerv Ment Dis. 2006;194(3):173-178.
4. Ayers BN, Forshaw MJ, Hunter MS. The menopause. The Psychologist. 2011;24:348-353.
5. Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med. 2011;41(9):1879-1888.
6. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63(4):385-390.
7. Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63(4):375-382.
8. Georgakis MK, Thomopoulos TP, Diamantaras AA, et al. Association of age at menopause and duration of reproductive period with depression after menopause: a systematic review and meta-analysis. JAMA Psychiatry 2016;73(2):139-149.
9. DiBonaventura MC, Wagner JS, Alvir J, et al. Depression, quality of life, work productivity, resource use, and costs among women experiencing menopause and hot flashes: a cross-sectional study [published online November 1, 2012]. Prim Care Companion CNS Disord. 2012;14(6): pii: PCC.12m01410. doi: 10.4088/PCC.12m01410.
10. Llaneza P, Garcia-Portilla MP, Llaneza-Suárez D, et al. Depressive disorders and the menopause transition. Maturitas. 2012;71(2):120-130.
11. Vivian-Taylor J, Hickey M. Menopause and depression: is there a link? Maturitas. 2014;79(2):142-146.
12. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey. 1: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29(2-3):85-96.
13. Friedman SH, Stankowski JE, Sajatovic M. Bipolar disorder in women. The Female Patient. 2007;32:15-24.
14. Soares C, Cohen L. The perimenopause, depressive disorders, and hormonal variability. Sao Paulo Med J. 2001;119(2):78-83.
15. Friedman SH, Sajatovic M, Schuermeyer IN, et al. Menopause-related quality of life in chronically mentally ill women. Int J Psychiatry Med. 2005;35(3):259-271.
16. Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry. 2015;72(7):714-726.
17. Carretti N, Florio P, Bertolin A et al. Serum fluctuations of total and free tryptophan levels during the menstrual cycle are related to gonadotrophins and reflect brain serotonin utilization. Hum Reprod. 2005;20(6):1548-1553.
18. Borrow AP, Cameron NM. Estrogenic mediation of serotonergic and neurotrophic systems: implications for female mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:13-25.
19. Hu LY, Shen CC, Hung JH et al. Risk of psychiatric disorders following symptomatic menopausal transition: a nationwide population-based retrospective cohort study. Medicine (Baltimore). 2016;95(6):e2800. doi: 10.1097/MD.0000000000002800.
20. Riecher-Rossler AW. Estrogens and schizophrenia. In: Bergemann N, Riecher-Rossler A, eds. Estrogen effects in psychiatric disorders. Wien, Austria: Springer-Verlag Wien; 2005:31-52.
21. Pope CJ, Oinonen K, Mazmanian D, et al. The hormonal sensitivity hypothesis: a review and new findings. Med Hypotheses. 2017;102:69-77.
22. Dennerstein L, Soares CN. The unique challenges of managing depression in mid-life women. World Psychiatry. 2008;7(3):137-142.
23. Caan B, LaCroix AZ, Joffe H, et al. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause. 2015;22(6):607-615.
24. Seeman MV. Psychosis in women: Consider midlife medical and psychological triggers. Current Psychiatry. 2010;9(2):64-68,75-76.
25. Sajatovic M, Friedman SH, Sabharwal J, et al. Clinical characteristics and length of hospital stay among older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression, and dementia. J Geriatr Psychiatry Neurol. 2004;17(1):3-8.
26. Grover S, Talwar P, Baghel R, et al. Genetic variability in estrogen disposition: potential clinical implications for neuropsychiatric disorders. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(8):1391-1410.
27. Kulkarni J, Gavrilidis E, Wang W, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry. 2015;20(6):695-702.
28. Kulkarni J, Gavrilidis E, Gwini SM, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry. 2016;73(9):947-954.
29. Brzezinski A, Brzezinski-Sinai NA, Seeman MV. Treating schizophrenia during menopause. Menopause. 2017;24(5):582-588.
30. Lange B, Mueller JK, Leweke FM, et al. How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review. Expert Opin Pharmacother. 2017;18(4):351-362.
31. Ballard KD, Kuh DJ, Wadsworth MEJ. The role of the menopause in women’s experiences of the ‘change of life.’ Sociology of Health & Illness. 2001;23(4):397-424.
32. Clayton AH, Ninan PT. Depression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women. Prim Care Companion J Clin Psychiatry. 2010;12(1):PCC.08r00747. doi: 10.4088/PCC.08r00747blu.

Mrs. J, age 49, presents to your psychiatric clinic. For the last few years, she has been experiencing night sweats and hot flashes, which she has attributed to being perimenopausal. Over the last year, she has noticed that her mood has declined; however, she has suffered several life events that she feels have contributed. Her mother was diagnosed with Alzheimer’s disease and had to move into a nursing home, which Mrs. J found very stressful. At the same time, her daughter left home for college, and her son is exploring his college options. Recently, Mrs. J has not been able to work due to her mood, and she is afraid she may lose her job as a consequence. She has struggled to talk to her husband about how she is feeling, and feels increasingly isolated. Over the last month, she has had increased problems sleeping and less energy; some days she struggles to get out of bed. She is finding it difficult to concentrate and is more forgetful. She has lost interest in her hobbies and is no longer meeting with her friends. She has no history of depression or anxiety, although she recalls feeling very low in mood for months after the birth of each of her children.

Are Mrs. J’s symptoms related to menopause or depression? What further investigations are necessary? Would you modify your treatment plan because of her menopausal status?

Women are at elevated risk of developing psychiatric symptoms and disorders throughout their reproductive lives, including during menopause. Menopause is a time of life transition, when women may experience multiple physical symptoms, including vasomotor symptoms (night sweats and hot flashes), sexual symptoms, and sleep difficulties. Depressive symptoms occur more frequently during menopause, and symptoms of schizophrenia may worsen.

Estrogen plays a role in mental illness throughout a woman’s life. In menopause, decreasing estrogen levels may correlate with increased mood symptoms, physical symptoms, and psychotic symptoms. As such, psychiatrists should consider whether collaboration regarding adjunctive hormone replacement therapy would be beneficial, and whether the benefits outweigh the potential risks. Otherwise, treatment of depression in menopause is similar to treatment outside of the menopausal transition, though serotonergic antidepressants may help target vasomotor symptoms while therapy may focus on role transition and loss. In this article, we review why women are at increased risk for mental illness during menopause, the role of estrogen, and treatment of mood and psychotic disorders during this phase of a woman’s life.

Increased vulnerability across the lifespan

The female lifecycle includes several periods of increased vulnerability to mental illness related to reproductive hormones and life changes. Compared with men, women have approximately twice the risk of developing depression in their lifetime.¹ With the onset of menarche, the increased risk of mental health problems begins (Table 1^1,2). Women are at elevated risk of mood disorders in both pregnancy and postpartum; approximately one-seventh to one-quarter of women experience postpartum depression, depending on the population studied. Finally, women are at risk of mood difficulties in the perimenopause. Those with a history of depression are at particularly elevated risk in the perimenopause.²

Continued to: Why menopause?

References

Unrelenting depression: ‘I would rather be dead than feel this way’

Psychiatric considerations in menopause

References

Increased vulnerability across the lifespan

Pages

Next Article: